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Neural stem cells
. They also provide a promising method for treating brain cancers by delivering chemotherapeutic agents directly to the tumour cells (reviewed in [3] ). On the other hand, multipotent subsets of NSCs such as radial glia are believed to generate all the phenotypically diverse cells that populate brain tumours (for review see [4] ). [5] ), neuroprotection and degeneration (reviewed in [6] and [7] ), learning and memory formation and pathological tumour malignancies (reviewed in [8] and [9] ). In particular NF-B has distinct functions in multiple immune cell types via the regulation of target genes essential for cell proliferation, survival, effector functions and cell trafficking [10] [11] [12] .
NF-B
The transcription factor NF-B plays a pivotal role in a variety of biological processes including innate and adaptive immunity (reviewed in
In the nervous system NF-B is known to mediate either neuroprotection or apoptosis in a stimulus depending manner [13] . Concerning [6] ). [43] . ([31, 32] 
TNF-␣
Thus, NSCs are exposed after migration to TNF at the area of inflammation. In this context, it is noteworthy that TNF-induced NF-B activity results in increased proliferation of NSCs
Inflammation, NF-B and cancer
Inflammation is prerequisite for wound healing, elimination of infections and regeneration after pathological situations via, inter alia, the migration, proliferation and differentiation of stem cells (see above). On the other hand, cancer is associated with maladaptive chronic inflammation.
In the 19 th century, Rudolf Virchov hypothesized that chronic inflammation may cause several malignancies including cancer [46] [47] [48] . [49] [50] [51] [52] [53] [54] [55] [56] . In addition brain tumours express the chemokine receptors CXCR4, CCR1, CCR3, CCR5 and CCR2 [57] [58] [59] .
Interestingly, one of the most prominent inflammatory cytokines -TNF-␣ (see above) -is known to activate NF-B strongly in several experimental cancer models and to act as a potent tumour promoter (reviewed in [9]). Brain tumours were demonstrated to express TNF receptors like TNFRI, TNFRII, DR6, Fas or Fn14 and the TNF receptor associated signalling molecules consisting of TRAIL-R1, TRAIL-R2, TRAIL, TRAF1, TRAF2 and TANK/I-TRAF
The role of NF-B in cancer development and progression has been extensively discussed ([8,16, 60-67 [51, [68] [69] [70] [71] [72] [73] [74] [75] [76] .
]). In particular, the activation of NF-B blocks apoptosis via modulation of anti-apoptotic target genes, such as c-IAP, bcl-2 and bcl-xL and mediates tumour cell proliferation via up-regulation of targets like cyclin-D1 and c-myc
It also induces resistance to chemotherapeutic agents. In fact, numerous genes involved in tumour initiation, promotion and metastasis are regulated by the NF-B pathway (for review see [16, 63] ). NF-B is constitutively active in most tumour specimens described to date (reviewed in [16] and [9] ). [79] . Nestin -an intermediate filament [80] , and Musashi, a RNA binding protein [81, 82] 
NSCs and brain cancer
NF-B target genes affecting NSCs and tumour formation
In this review, we focus on NF-B targets regulating cell-cycle, anti-apoptosis, cellular ageing and multidrug-resistance. [98, 99] [101] .
Several tumour specimens like malignant astrocytomas, especially glioblastomas show elevated levels of the c-myc proto-oncogene [51]. c-myc is a welldescribed NF-B target with functional B-binding site in its promoter region
. In addition, in their study Bouragel-Rey and colleagues demonstrated that activated NF-B strongly induces c-myc [100]. Recently, Faria and colleagues showed a positive correlation between c-Myc expression and the histopathologial grade and the proliferative status of astrocytic tumours
Also, many human medulloblastomas express significantly elevated levels of myc oncogenes correlated with worse clinical outcome [102] [103] [104] . The c-Myc oncoprotein is well described to be a potent mitogen for neural precursors in vitro and in vivo [105] . [76, 109, 110] .
In a recent study Xiaohua et al. showed that in NSCs, an elevated expression of c-Myc and neural restricted silencer factor (NRSF), a transcriptional repressor of neuronal differentiation causes cerebellar tumours [106]. Additionally, c-Myc enhances sonic-hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors [107]. Interestingly, TNF-␣ stimulated rat NSCs showed highly elevated c-Myc expression compared to untreated control (Widera et al. unpublished data). All these data suggest c-myc to be one of the NF-B target genes responsible for induction of tumours from NSCs in inflammatory situations. A further NF-B target gene known to trigger proliferation of tumour cells is cyclin D1. Cyclin D1 has two NF-B binding sites in the promoter region. The stimulation of the transcription of cyclin D1 by NF-B results in increased proliferation of several cell types (reviewed in [108]). Similar to c-myc, Cyclin D1 is widely up-regulated in several brain tumours like meningiomas, olfactory neuroblastomas and gliomas and is closely related to oncogenesis, proliferation of tumour cells and worse clinical prognosis
In contrast loss of cyclin D1 suppresses medulloblastoma formation [111] . The NF-B induced upregulation of Cyclin D1 has been identified as one of the crucial events in cell cycle progression of tumour cells [75, 112] . [113, 114] . Thus, cyclin D1 seems to be another NF-B target gene potentially responsible for tumour formation and progression. [116] and [117] [119] . Furthermore, it has been demonstrated that putative stem cells from solid tissues may also possess this SP phenotype [120] . A robust expression of ABC transporters ABCA2, ABCA3, ABCB1 and ABCG2 in NSCs has been described (reviewed in [121] ). This fact suggests a potential role of these NF-B targets in tumour biology. [31, [122] [123] [124] . Physiologically, NSCs proliferate slowly and asymmetrically or rest in the G0-Phase of the cell cycle. In an inflammatory environment, they start to proliferate rapidly and symmetrically [94] . This may be attributable to the release of pro-inflammatory cytokines, such as TNF-␣ from the injured tissue. In addition, the expression of mitogens like FGF-2 is increased in inflammation [125] . The expression of FGF and FGF receptors seems to be crucial for symmetrical division of embryonic and NSCs (self-renewal) [60] [61] [62] . [64, 65] .
In NSCs, Cyclin D1 seems to act in a similar manner. TNF-␣ treated rat NSCs show highly up-regulated Cyclin D1 expression and significantly increased proliferation compared to control cells [31]. This finding is in accordance with the hypothesis that inflammation activates the transcription factor NF-B
Fig. 1 Neural stem cells (NSC) division in physiological situation and in acute inflammation. Physiologically, NSCs proliferate slowly and asymmetrically generating more committed precursors or differentiated cells. In an inflammatory environment, NSCs might start to proliferate rapidly and symmetrically in response to pro-inflammatory cytokines such as TNF-␣. The pro-inflammatory stimuli activate the transcription factor NF-B. After acute inflammation is attenuated, NF-B becomes deactivated and NSCs switch back to the asymmetrical mode of division. resulting in transcription of target genes that induce proliferation. In contrast, dexamethasone induced ubiquitination of Cyclin D1 or down-regulation of Cyclin D1 by GATA2 led to decreased proliferation of NSCs
In addition to the deregulated cell cycle control, several pathways regulating apoptosis are also disrupted in brain tumours. Thus, malignant tumours often show intense resistance to apoptosis. NF-B is known to directly activate the apoptosis inhibitors Bcl-xL and Bcl-2. In tumours a positive correlation between high expression of NF-B and up-regulated levels of the target genes Bcl-xL and Bcl-2 has been demonstrated [69]. This phenomenon might partially explain the apoptosis resistance of tumours through NF-B driven induction of anti-apoptotic genes like Bcl-xL and Bcl-2. One problem of many brain malignant tumours is their resistance to chemotherapy [115]. This observable fact can be explained by the expression of ATPbinding cassette (ABC) drug efflux transporters (reviewed in
Conclusion
Inflammatory signals and conditions have been described as inducing NSC proliferation via activation of the NF-B pathway
Recently, evidence was provided that FGF-2 activates NF-B [63]. In addition, FGF-2 acts in an antiapoptotic and pro-proliferative manner through activated NF-B
After attenuation of the acute phase of the inflammation and a decrease in local concentration of proinflammatory signals NSCs decrease their rate of proliferation and proceed either to slow proliferation or to the resting state (G0-Phase) (see Fig. 1 ).
In contrast, during chronic inflammation, NSCs are permanently exposed to proliferation signals. Fast proliferation holds a much higher risk of mutation than slow cell division. These fast symmetric divisions may promote the expansion of NSCs and lead to aneuploidy (see Fig. 2 
